8-K - SNYR - Equibles

UNITED STATES

SECURITIES AND EXCHANGECOMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section13 or 15(d) of the

Securities ExchangeAct of 1934

Date of Report (Date of

earliest event reported): February 27, 2026

SYNERGY CHC CORP.

(Exact name of registrant as specified in its charter)

Nevada	001-42374	99-0379440
(State or Other Jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification No.)
865 Spring Street, Westbrook, Maine	04092
---	---
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code:

(207) 321-2350

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.00001 per share	SNYR	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On February 27, 2026, Synergy CHC Corp. (the “Company”) was notified by Gravity Pharma General Trading LLC (“Gravity”) that Gravity was terminating, ab initio, the Brand License Agreement, dated March 31, 2025, by and between the Company and Gravity (as amended by Amendment No. 1 to the Brand License Agreement, dated June 30, 2025, the “Brand License Agreement”).

The Brand License Agreement provided for an exclusive license to sell and market certain FOCUSfactor and Flat Tummy Co. products (the “Licensed IP”) in the United Arab Emirates and Turkey (the “Territory”) in exchange for an aggregate license fee of $2.9 million. The Company previously accounted for the license fee as revenue.

The Company continues to pursue the registration and marketing of the Licensed IP in the Territory.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 3, 2026
	SYNERGY CHC CORP.
	By:	/s/ Jack Ross
	Name:	Jack Ross
	Title:	Chief Executive Officer